

Michael J Overman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/180270/publications.pdf>

Version: 2024-02-01

182
papers

13,314
citations

36303
51
h-index

26613
107
g-index

184
all docs

184
docs citations

184
times ranked

16022
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	10.7	2,058
2	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	1.6	1,525
3	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	4.9	758
4	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	16.8	353
5	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	7.1	348
6	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	1.6	283
7	Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. <i>Journal of Clinical Oncology</i> , 2013, 31, 17-22.	1.6	273
8	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	7.1	237
9	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	30.7	236
10	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	7.0	225
11	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	4.1	212
12	Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2009, 27, 2598-2603.	1.6	208
13	Epithelial-Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression. <i>Clinical Cancer Research</i> , 2015, 21, 899-906.	7.0	199
14	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	9.4	192
15	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. <i>Journal of Clinical Oncology</i> , 2010, 28, 2549-2555.	1.6	188
16	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546.	7.1	154
17	Small bowel adenocarcinomas: existing evidence and evolving paradigms. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 534-544.	27.6	140
18	The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 213-221.	4.1	131

#	ARTICLE	IF	CITATIONS
19	A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. <i>Annals of Surgical Oncology</i> , 2012, 19, 1439-1445.	1.5	124
20	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	1.7	124
21	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1131-1141.	6.3	116
22	Chemotherapy with 5-Fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. <i>Cancer</i> , 2008, 113, 2038-2045.	4.1	109
23	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. <i>Cancer</i> , 2010, 116, 316-322.	4.1	109
24	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	2.3	108
25	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. <i>Cell Reports</i> , 2016, 14, 907-919.	6.4	107
26	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	1.6	106
27	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	4.3	105
28	Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 239-247.	3.8	96
29	Portal Hypertension Associated With Oxaliplatin Administration: Clinical Manifestations of Hepatic Sinusoidal Injury. <i>Clinical Colorectal Cancer</i> , 2009, 8, 225-230.	2.3	94
30	Prognostic value of lymph node evaluation in small bowel adenocarcinoma. <i>Cancer</i> , 2010, 116, 5374-5382.	4.1	93
31	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1109-1133.	4.9	92
32	Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix. <i>Annals of Surgery</i> , 2013, 257, 1072-1078.	4.2	91
33	Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3501-3501.	1.6	90
34	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2014, 22, 1223-1231.	2.2	86
35	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	1.8	86
36	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	4.3	82

#	ARTICLE	IF	CITATIONS
37	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 1352-1361.	6.4	81
38	Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. <i>Acta Oncologica</i> , 2010, 49, 474-479.	1.8	79
39	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	4.1	78
40	Goblet Cell Carcinoid Tumor, Mixed Goblet Cell Carcinoid-Adenocarcinoma, and Adenocarcinoma of the Appendix: Comparison of Clinicopathologic Features and Prognosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 782-790.	2.5	75
41	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	3.7	75
42	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. <i>Investigational New Drugs</i> , 2008, 26, 445-454.	2.6	74
43	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	7.0	70
44	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	1.8	69
45	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	2.5	65
46	Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors. <i>Cancer Investigation</i> , 2008, 26, 794-799.	1.3	62
47	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017, 24, 187-193.	1.5	62
48	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
49	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	4.2	61
50	Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e207911.	5.9	59
51	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	2.9	59
52	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 208-211.	6.3	56
53	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	1.8	53
54	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.	6.3	53

#	ARTICLE	IF	CITATIONS
55	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. PLoS ONE, 2013, 8, e65144.	2.5	50
56	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4146-4154.	7.0	50
57	Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery, 2017, 161, 332-340.	1.9	50
58	Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports, 2019, 21, 5.	2.5	50
59	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	4.1	49
60	Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i> ^{V600E} metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 12-12.	1.6	49
61	From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. Journal of Clinical Oncology, 2015, 33, 3583-3590.	1.6	46
62	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-“Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	3.0	46
63	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiotherapy and Oncology, 2017, 122, 146-151.	0.6	45
64	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: A single-center, open-label, phase 2 study. Cancer, 2017, 123, 1011-1017.	4.1	45
65	Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1135-1141.	4.9	45
66	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
67	Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer, 2010, 116, 1446-1453.	4.1	43
68	High-level Microsatellite Instability in Appendiceal Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1192-1200.	3.7	43
69	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	1.8	42
70	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	1.7	42
71	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist, 2013, 18, 1270-1277.	3.7	41
72	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clinical Colorectal Cancer, 2016, 15, e1-e7.	2.3	41

#	ARTICLE	IF	CITATIONS
73	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	7.0	41
74	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	4.1	40
75	Facile profiling of molecular heterogeneity by microfluidic digital melt. <i>Science Advances</i> , 2018, 4, eaat6459.	10.3	37
76	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.	9.4	37
77	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 73-81.	2.3	36
78	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	4.1	35
79	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 5041-5050.	2.8	35
80	Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. <i>Oncologist</i> , 2018, 23, 277-e26.	3.7	34
81	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	2.3	34
82	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 996-1002.	4.2	34
83	Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. <i>Cancer Medicine</i> , 2016, 5, 239-247.	2.8	33
84	EGFR-Targeted Therapies in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1259-1270.	1.3	32
85	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	1.5	32
86	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	6.4	32
87	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	7.0	32
88	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 1869-1874.	2.4	31
89	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1385-1394.	7.0	31
90	Comprehensive Clinical and Molecular Characterization of KRAS ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	3.0	31

#	ARTICLE	IF	CITATIONS
91	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. <i>Annals of Surgical Oncology</i> , 2017, 24, 2646-2654.	1.5	30
92	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	1.5	30
93	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	17.0	30
94	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1663-1670.	7.0	30
95	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	6.4	29
96	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
97	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. <i>Blood</i> , 2013, 122, 580-580.	1.4	27
98	A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2015, 22, 3640-3646.	1.5	26
99	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	5.0	26
100	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.	6.3	26
101	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <i>Annals of Surgical Oncology</i> , 2018, 25, 179-187.	1.5	26
102	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3531-3531.	1.6	26
103	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	2.5	25
104	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.	7.0	25
105	Recent advances in the management of adenocarcinoma of the small intestine. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 90-6.	0.7	25
106	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	2.8	24
107	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instabilityâ€‘high (MSI-H) tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 670-670.	1.6	24
108	Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 2792-2798.	2.0	23

#	ARTICLE	IF	CITATIONS
109	Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS ONE, 2016, 11, e0154985.	2.5	22
110	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical Cancer Research, 2019, 25, 641-651.	7.0	21
111	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clinical Cancer Research, 2021, 27, 120-130.	7.0	21
112	Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open, 2020, 5, e000960.	4.5	20
113	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut, 2018, 67, 1095-1102.	12.1	19
114	Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. Journal of the American College of Surgeons, 2021, 233, 82-89e1.	0.5	19
115	Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Human Pathology, 2014, 45, 1015-1023.	2.0	18
116	<scp>ABO</scp> nonâ€œO type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Medicine, 2015, 4, 1651-1658.	2.8	18
117	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. British Journal of Cancer, 2020, 123, 1262-1270.	6.4	18
118	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	3.8	17
119	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 137-147.e1.	2.3	17
120	Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Scientific Reports, 2020, 10, 13255.	3.3	17
121	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. British Journal of Surgery, 2022, 109, 489-492.	0.3	17
122	Fatal Diffuse Alveolar Damage Associated with Oxaliplatin Administration. Clinical Colorectal Cancer, 2011, 10, 198-202.	2.3	16
123	Underreporting of Research Biopsies from Clinical Trials in Oncology. Clinical Cancer Research, 2017, 23, 6450-6457.	7.0	15
124	A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Supportive Care in Cancer, 2015, 23, 661-670.	2.2	14
125	Bioactive lipid metabolism in platelet â€œfirst responderâ€•and cancer biology. Cancer and Metastasis Reviews, 2018, 37, 439-454.	5.9	14
126	Virtual Clinical Trials in Oncologyâ€”Overview, Challenges, Policy Considerations, and Future Directions. JCO Clinical Cancer Informatics, 2021, 5, 421-425.	2.1	14

#	ARTICLE	IF	CITATIONS
127	Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	7.0	14
128	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	2.8	14
129	Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2914-2919.	1.5	13
130	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	2.8	13
131	Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2022, 234, 474-483.	0.5	13
132	A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 865-872.	4.9	12
133	Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. <i>BMC Cancer</i> , 2019, 19, 965.	2.6	12
134	Rare but Real: Management of Small Bowel Adenocarcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 189-193.	3.8	12
135	Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 668.	2.6	11
136	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017, 17, 331.	2.6	11
137	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	2.4	11
138	Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 402.	7.1	11
139	Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. <i>JAMA Network Open</i> , 2021, 4, e2119934.	5.9	11
140	Mismatch Repair-Proficient Colorectal Cancer: Finding the Right Time to Respond. <i>Clinical Cancer Research</i> , 2019, 25, 5185-5187.	7.0	10
141	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	3.3	10
142	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	2.8	10
143	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
144	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	5.9	10

#	ARTICLE	IF	CITATIONS
145	Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 3954-3963.	1.5	9
146	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	2.8	9
147	Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. <i>Oncologist</i> , 2019, 24, 483-490.	3.7	8
148	Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. <i>Oncologist</i> , 2019, 24, e384-e386.	3.7	8
149	Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. <i>Human Pathology</i> , 2015, 46, 1315-1322.	2.0	7
150	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. <i>Annals of Surgical Oncology</i> , 2017, 24, 3667-3672.	1.5	7
151	Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. <i>Oncologist</i> , 2020, 25, e1807-e1811.	3.7	7
152	Molecular Landscape of Small Bowel Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1287.	3.7	7
153	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. <i>Investigational New Drugs</i> , 2013, 31, 1375-1383.	2.6	6
154	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. <i>BMC Medical Research Methodology</i> , 2018, 18, 169.	3.1	6
155	Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury. <i>Oncotarget</i> , 2018, 9, 34857-34858.	1.8	6
156	Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. <i>Cancers</i> , 2022, 14, 1137.	3.7	5
157	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	2.5	5
158	Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?. <i>Journal of Hepatology</i> , 2017, 67, 10-11.	3.7	4
159	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. <i>JAMA Oncology</i> , 2018, 4, 1041.	7.1	4
160	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , 2021, 5, 94.	5.4	4
161	Worsening of thrombotic thrombocytopenic purpura symptoms associated with desmopressin administration. <i>Thrombosis and Haemostasis</i> , 2004, 92, 886-7.	3.4	4
162	Adjuvant Chemotherapy for Resected Periapillary Adenocarcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1855.	7.4	3

#	ARTICLE	IF	CITATIONS
163	Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. <i>Oncologist</i> , 2015, 20, e3-4.	3.7	3
164	Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e103-e108.	0.4	3
165	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	2.3	3
166	Cancer of Unknown Primary Presenting as Boneâ€Predominant or Lymph Nodeâ€Only Disease: A Clinicopathologic Portrait. <i>Oncologist</i> , 2021, 26, e650-e657.	3.7	3
167	Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. <i>BMJ Open</i> , 2022, 12, e057693.	1.9	3
168	Lost in Translation: A Fisherman's Tale. <i>Journal of Clinical Oncology</i> , 2011, 29, 3832-3833.	1.6	2
169	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series. <i>Acta OncolÃ³gica</i> , 2013, 52, 1044-1046.	1.8	2
170	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	2.3	2
171	Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 223-232.e1.	1.2	2
172	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	1.4	2
173	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. <i>Clinical Colorectal Cancer</i> , 2020, 19, e189-e199.	2.3	1
174	The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. <i>Blood</i> , 2007, 110, 1289-1289.	1.4	1
175	Inducing Hypermutability to Promote Antiâ€PD-1 Therapy Response. <i>Cancer Discovery</i> , 2022, 12, 1612-1614.	9.4	1
176	Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases. <i>Clinical Colorectal Cancer</i> , 2008, 7, 338-342.	2.3	0
177	Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea.. , 2018, 08, .		0
178	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2268-2274.	1.4	0
179	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	0
180	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 450-450.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood, 2013, 122, 3028-3028.	1.4	0
182	Letting go of the physical exam: embracing telehealth solutions to oncology. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	0